ALNYLAM PHARMACEUTICALS, INC.
ALNYLAM PHARMACEUTICALS, INC. (ALNY): 25 pipeline candidates · 10 upcoming catalysts · ~14 mo cash runway · 35 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
13.7 months
D/E 5.29 · 0% dilution
Lead: Phase 2
25 candidates
10 upcoming, next in ~12d
0 buys · 247 sells (180d)
A transparent, data-derived signal for ALNYLAM PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$37.2B
Cash
$1.7B
Quarterly Burn
$697.6M
Runway
13.7 mo
Revenue
$1.1B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (25 candidates)
| Drug | Phase |
|---|---|
| aln-2232 | Phase 2 |
| ALN-4285 | Phase 2 |
| ALN-4324 | Phase 2 |
| aln-4915 | Phase 1 |
| ALN-5288 | Phase 1 |
| aln-6222 | Phase 1/Phase 2 |
| ALN-6400 | Phase 2 |
| ALN-AGT01 | Phase 2 |
| ALN-AGT01 RVR | Phase 2 |
| ALN-APP | Phase 2 |
Showing 10 of 25 candidates. Sign up for full pipeline.
Upcoming Catalysts (10)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
784
Total value held
$33.98B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 14,579,166 | $4.82B |
| vanguard capital management llc | 11,893,412 | $3.94B |
| blackrock, inc. | 10,444,908 | $3.46B |
| vanguard portfolio management llc | 6,491,280 | $2.15B |
| state street corp | 3,322,698 | $1.10B |
| geode capital management, llc | 2,660,385 | $884.6M |
| baillie gifford & co | 2,493,866 | $825.1M |
| two sigma investments, lp | 1,992,577 | $659.3M |
| wellington management group llp | 1,935,925 | $640.5M |
| dodge & cox | 1,929,253 | $638.3M |
Showing top 10 of 784 institutional holders of ALNYLAM PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ALNYLAM PHARMACEUTICALS, INC.'s pipeline?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has 25 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ALNYLAM PHARMACEUTICALS, INC.'s lead drug candidate?
ALNYLAM PHARMACEUTICALS, INC.'s most advanced tracked candidate is aln-2232 (Phase 2) for Obesity.
What is ALNYLAM PHARMACEUTICALS, INC.'s next catalyst?
ALNYLAM PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharm" — expected June 30, 2026.
What is ALNYLAM PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ALNYLAM PHARMACEUTICALS, INC. has approximately 13.7 months of cash runway.
What is ALNYLAM PHARMACEUTICALS, INC.'s market capitalization?
ALNYLAM PHARMACEUTICALS, INC.'s market capitalization is approximately $37.2B.
Get the full picture on ALNYLAM PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.